ARTICLE | Emerging Company Profile
Redirecting viral immunity
How Revitope's APEC technology redirects viral immunity against cancer
June 20, 2016 7:00 AM UTC
Revitope Oncology Inc. is developing a novel antibody conjugate technology that aims to harness the body's naturally potent T cell response against cytomegalovirus and redirect it against cancer cells. The company's candidates consist of antibody peptide epitope complexes, or APECs, that conjugate an antibody targeting a tumor-specific antigen to a peptide that contains a protease cleavage site and a CMV epitope.
According to President and CEO Julie Cherrington, 70-90% of adults have a natural immunity against CMV. The immune response against CMV is up to a thousand times stronger than is typically observed against cancer, with up to 50% of T cells being directed against CMV at any one time. ...